03 · Outlook
Outlook
Bookmarks need a Mind Club sign-in. How sign-in works
Outlook across your briefsOur 30, 60 and 90 day view is unchanged from Thursday: rates and a falling market may be the main risk, while drugmakers keep licensing early platforms.
| Horizon | What we expect | What would change it | Odds |
|---|---|---|---|
| 30 days | Goal dates on 11.22, 11.27 and 11.30, the CMS negotiated prices due by 11.30 and the 12.09 FOMC, where a hike is priced in futures, as reported, set the news flow | A hold or a 50 basis point move at the 12.09 FOMC | · |
| 60 days | SUO (12.02), ASH (12.12 to 12.15) and year-end goal dates lead the calendar | A biopharma acquisition of $5B or more (call 9 in 15) | · |
| 90 days | RAS drugs in pancreatic cancer may draw more first-line data and trials, with randomized results still ahead | A further rise in the 10-year yield, now 5.04% | · |
Dates from 14 Verified Catalyst Calendar; odds only where a logged call in 15 sets them. Analysis
RED TEAM
Our outlook has not moved while the market fell six days running, as reported. If the sell-off spreads, the risk to small biotech may be larger than our rates line suggests. Analysis